We conducted a comprehensive review of the literature on clinical studies investigating the efficacy of emerging biologics in CRSwNP, with a focus on randomized controlled trials.
Conclusions
There appears to be promising evidence to support the safety and efficacy of biologics in CRSwNP with and without asthma for select patients. However, additional large-scale randomized studies with longer follow-up are necessary to determine which patients would benefit the most from these novel systemic treatments.
Implications for Practice
Chronic rhinosinusitis with nasal polyposis refractory to medical and surgical therapy remains a challenging clinical problem for otolaryngologists. However, emerging biologic therapies may offer a new therapeutic option for such patients with recalcitrant disease.
RosenfeldRMPiccirilloJFChandrasekharSS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;52:S1-S39.
2.
RudmikL.Economics of chronic rhinosinusitis. Curr Allergy Asthma Rep. 2017;17:20.
3.
FokkensWJLundVJMullolJ, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50:1-12.
4.
MeltzerEOHamilosDLHadleyJA, et al. Rhinosinusitis: establishing definitions for clinical research and patient care. Otolaryngol Head Neck Surg. 2004;131:S1-62.
5.
OrlandiRRKingdomTTHwangPH, et al. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(suppl 1):S22-S209.
6.
SchwartzJSTajudeenBACohenNA. Medical management of chronic rhinosinusitis—a review of traditional and novel medical therapies. Expert Opin Investig Drugs. 2017;26:1123-1130.
7.
LoftusCASolerZMKoochakzadehS, et al. Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors. Int Forum Allergy Rhinol. 2020;10:199-207.
8.
BachertCZhangNHellingsPWBousquetJ. Endotype-driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141:1543-1551.
9.
HanJK. Subclassification of chronic rhinosinusitis. Laryngoscope. 2013;123(suppl 2):S15-S27.
10.
Kortekaas KrohnIShikhagaieMMGolebskiK, et al. Emerging roles of innate lymphoid cells in inflammatory diseases: clinical implications. Allergy. 2018;73:837-850.
11.
TomassenPVandeplasGVan ZeleT, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137:1449-1456 e1444.
12.
HoggardMWaldvogel-ThurlowSZoingM, et al. Inflammatory endotypes and microbial associations in chronic rhinosinusitis. Front Immunol. 2018;9:2065.
13.
TurnerJHChandraRKLiPBonnetKSchlundtDG. Identification of clinically relevant chronic rhinosinusitis endotypes using cluster analysis of mucus cytokines. J Allergy Clin Immunol. 2018;141:1895-1897 e1897.
14.
LiaoBLiuJXLiZY, et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy. 2018;73:1459-1469.
15.
NormansellRWalkerSMilanSJWaltersEHNairP. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014:CD003559.
16.
GevaertPCalusLVan ZeleT, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131:110-116 e111.
17.
PintoJMMehtaNDiTineoMWangJBaroodyFMNaclerioRM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48:318-324.
18.
HongCJTsangACQuinnJGBonaparteJPStevensAKiltySJ. Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review. Syst Rev. 2015;4:166.
CastroMMathurSHargreaveF, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1125-1132.
22.
LeckieMJten BrinkeAKhan Jetal. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000; 356:2144-2148.
23.
PavordIDKornSHowarthP, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651-659.
24.
FalaL. Nucala (mepolizumab): first IL-5 antagonist monoclonal antibody FDA approved for maintenance treatment of patients with severe asthma. Am Health Drug Benefits. 2016;9:106-110.
25.
GevaertPLang-LoidoltDLacknerA, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118:1133-1141.
26.
GevaertPVan BruaeneNCattaertT, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128:989-995 e981-988.
27.
RiveroALiangJ. Anti-IgE and anti-IL5 biologic therapy in the treatment of nasal polyposis: a systematic review and meta-analysis. Ann Otol Rhinol Laryngol. 2017;126:739-747.
28.
BachertCSousaARLundVJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140:1024-1031 e1014.
CastroMCorrenJPavordID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486-2496.
32.
BachertCMannentLNaclerioRM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315:469-479.
33.
BachertCHanJKDesrosiersM, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638-1650.
34.
HarveyRJSnidvongsKKalishLHOakleyGMSacksR. Corticosteroid nasal irrigations are more effective than simple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery. Int Forum Allergy Rhinol. 2018;8:461-470.
35.
LamKKernRCLuongA. Is there a future for biologics in the management of chronic rhinosinusitis?Int Forum Allergy Rhinol. 2016;6:935-942.
36.
ShawJLFakhriSCitardiMJ, et al. IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps. Am J Respir Crit Care Med. 2013;188:432-439.
37.
KimDKJinHREunKM, et al. The role of interleukin-33 in chronic rhinosinusitis. Thorax. 2017;72:635-645.
38.
SongWWangCZhouJPanSLinS. IL-33 expression in chronic rhinosinusitis with nasal polyps and its relationship with clinical severity. ORL J Otorhinolaryngol Relat Spec. 2017;79:323-330.
39.
LuoXLiCWangY, et al. Interleukin-33 promotes Th2/Th17 response in eosinophilic and non-eosinophilic nasal polyps. ORL J Otorhinolaryngol Relat Spec. 2020;82:34-39.
40.
NCT02170337. A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 282 in health subjects and subjects with chronic rhinosinusitis with nasal polyps. Updated June1, 2016. https://clinicaltrials.gov/ct2/show/results/NCT02170337
41.
NCT02743871. Study of PF-06817024 in healthy subjects, in patients with chronic rhinosinusitis with nasal polyps and in patients with atopic dermatitis. Updated September6, 2019. https://clinicaltrials.gov/ct2/show/results/NCT02743871
WangWWLuDMZhengMZhangJGZhangB. TSLP regulates eotaxin-1 production by nasal epithelial cells from patients with eosinophilic CRSwNP. Rhinology. 2018;56:370-377.
44.
NagarkarDRPoposkiJATanBK, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;132:593-600 e512.
45.
LiuTLiTLZhaoF, et al. Role of thymic stromal lymphopoietin in the pathogenesis of nasal polyposis. Am J Med Sci. 2011;341:40-47.
46.
CorrenJParnesJRWangL, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936-946.
47.
IqbalIZKaoSSOoiEH. The role of biologics in chronic rhinosinusitis: a systematic review. Int Forum Allergy Rhinol. 2020;10:165-174.
48.
ChongLYPiromchaiPSharpS, et al. Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2020;2:CD013513.
49.
LaidlawTMBuchheitKM. Biologics in chronic rhinosinusitis with nasal polyposis. Ann Allergy Asthma Immunol. 2020;124:326-332.
50.
FokkensWJLundVBachertC, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74:2312-2319.
51.
AndersonWCIIISzeflerSJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic?Ann Allergy Asthma Immunol. 2019;122:367-372.
52.
ScangasGAWuAWTingJY, et al. Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Laryngoscope. 2020. doi:10.1002/lary.28648
